CryoPort (NASDAQ:CYRX) posted its quarterly earnings results on Thursday. The consumer goods maker reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.02, Briefing.com reports. The business had revenue of $9.58 million during the quarter, compared to analysts’ expectations of $9.49 million. CryoPort had a negative net margin of 35.71% and a negative return on equity of 17.32%. The firm’s quarterly revenue was up 81.1% compared to the same quarter last year. During the same period last year, the company posted ($0.07) earnings per share.
NASDAQ CYRX traded down $0.25 during trading on Friday, reaching $14.03. The company’s stock had a trading volume of 762,100 shares, compared to its average volume of 379,665. The stock has a market capitalization of $526.06 million, a PE ratio of -45.26 and a beta of 0.77. The company has a current ratio of 17.73, a quick ratio of 17.68 and a debt-to-equity ratio of 0.17. The business has a 50-day moving average price of $15.05 and a 200-day moving average price of $17.84. CryoPort has a 1-year low of $8.28 and a 1-year high of $25.02.
Several analysts recently commented on CYRX shares. Leerink Swann started coverage on shares of CryoPort in a report on Monday, July 15th. They set a “buy” rating and a $24.00 price target for the company. B. Riley set a $26.00 price target on shares of CryoPort and gave the stock a “buy” rating in a report on Friday, July 19th. ValuEngine upgraded shares of CryoPort from a “hold” rating to a “buy” rating in a report on Friday, November 1st. Svb Leerink reiterated an “outperform” rating on shares of CryoPort in a research note on Monday, July 15th. Finally, BidaskClub cut shares of CryoPort from a “sell” rating to a “strong sell” rating in a research note on Saturday, October 5th. One equities research analyst has rated the stock with a sell rating and five have assigned a buy rating to the stock. CryoPort presently has an average rating of “Buy” and an average price target of $24.00.
CryoPort, Inc engages in the provision of logistics solutions to the life science industry. It also provides logistics solutions for biologic materials such as immunotherapies, stem cells, CAR-T cells, and reproductive cells for clients worldwide, including points-of-care, clinical research organizations central laboratories, biopharmaceuticals, contract manufacturing, health centers, and university researchers.
Read More: What are the benefits of investing in REITs?
Receive News & Ratings for CryoPort Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoPort and related companies with MarketBeat.com's FREE daily email newsletter.